55/100B68.830
USD
-1.46
(-2.08%)
Market Open
Last updated: · Delayed 15 min
Fair valueNot reliable
Q4 FY2026 · Earnings report
EPS estimate -1.16Revenue estimate 46.30B
Q4 FY2026 · Earnings report
EPS estimate -1.16Revenue estimate 46.30B
If you had invested in Centene ago, it would be worth $2,773 today, against $4,096 in SPY and $6,368 in QQQ.
Arincen ScoreWhat is the Arincen Score? The Arincen Score grades a company out of 100 from 30 checks on its own reported figures, five checks in each of six parts.Beta
55/100
Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.
Profitability2
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Cash2.5
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Valuation7.5
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Growth6.7
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Financial strength7.5
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Shareholders6.7
Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.
Figures to FY2025; the price as of today.
Centene key facts
- StyleWhat does a stock's style mean? The style label sorts a stock as growth, value, dividend, blend or speculative, with a 1 to 10 meter showing how strongly it fits.
- Growth stock · 10.0/10Growth 10.0 · Value 6.2
- Day range
- 68.680 – 70.840
- 52-week range
- 31.630 – 78.080
- Market capitalizationWhat is market capitalization? Market cap is what the stock market values a whole company at: its share price times the number of its shares outstanding.
- 34.08B USD
- P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 23.25
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 2.50
- EPSWhat is EPS (earnings per share)? EPS (earnings per share) is a company's net income divided by its number of shares: the profit that belongs to each share over a period.
- 2.96
- EPS growth forecast (FY2026)
- +156.7%
- Volume
- 19,953
- BetaWhat is beta in stocks? Beta measures how much a stock tends to move when the whole market moves: 1 moves with it, under 1 is calmer, over 1 swings more.
- 1.08
- ESG scoreWhat is an ESG score? An ESG score rates how a company handles the environment, its people and its governance, out of 100. Higher is better.
- 58.1/100Environment 55 · Social 53 · Governance 66
- Sector
- Healthcare
- Industry
- Medical - Healthcare Plans
- CEO
- Sarah McGinty London
- Employees
- 61K
- Website
- centene.com
- IPO date
- 13 Dec 2001
Centene earningsWhat is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
Next earnings · Q4 FY2026
EPS estimate
-1.16 USD
Revenue estimate
46.30B USD
Last quarter · Q3 FY2026
EPS0.58Beat +506.1%Revenue50.65BBeat +7.5%
Revenue
ReportedEstimate
EPS
ReportedEstimate
| Period | Report date | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|---|
| Q3 FY2027 | 0.64 | — | — | +11.08% | 49.07B | — | — | -3.11% | |
| Q2 FY2027 | 2.36 | — | — | -6.07% | 49.40B | — | — | -7.79% | |
| Q1 FY2027 | 3.40 | — | — | +0.96% | 48.85B | — | — | -2.19% | |
| Q4 FY2026 | -1.16 | — | — | — | 46.30B | — | — | -6.88% | |
| Q3 FY2026 | 0.10 | 0.58 | +506.06% | +16.00% | 47.12B | 50.65B | +7.49% | +1.93% | |
| Q2 FY2026 | 1.09 | 2.51 | +130.28% | — | 47.64B | 53.58B | +12.47% | +9.92% | |
| Q1 FY2026 | 2.23 | 3.37 | +51.12% | +16.21% | 47.53B | 49.94B | +5.08% | +7.13% | |
| Q4 FY2025 | -1.22 | -1.19 | +2.46% | -248.75% | 48.41B | 49.73B | +2.71% | +21.86% | |
| Q3 FY2025 | -0.14 | 0.50 | +445.42% | -69.14% | 47.72B | 49.69B | +4.12% | +18.24% | |
| Q2 FY2025 | 0.11 | -0.16 | -243.37% | -106.61% | 44.14B | 48.74B | +10.44% | +22.36% |
| Period | EPS estimate | Reported EPS | Surprise | EPS growth | Revenue estimate | Reported revenue | Surprise | Revenue growth |
|---|---|---|---|---|---|---|---|---|
| FY2028 | 6.63 | — | — | +19.58% | 199.41B | — | — | +2.18% |
| FY2027 | 5.54 | — | — | +5.35% | 195.15B | — | — | -2.53% |
| FY2026 | 5.26 | — | — | +156.70% | 200.21B | — | — | +2.79% |
| FY2025 | 2.03 | 2.05 | +0.77% | -71.13% | 193.57B | 194.78B | +0.62% | +19.44% |
| FY2024 | 6.84 | 7.10 | +3.87% | +6.61% | 161.26B | 163.07B | +1.12% | +5.89% |
| FY2023 | 6.58 | 6.66 | +1.23% | +15.63% | 150.81B | 154.00B | +2.11% | +6.54% |
| FY2022 | 5.73 | 5.76 | +0.57% | +11.84% | 144.42B | 144.55B | +0.08% | +14.74% |
Analysts' estimates for FY2026 over the last 7 days:EPS Revenue How the estimates moved
Centene analyst forecastWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
12-month price target
75.43 USD
+9.59%
Analysts' 1-year price targets range from 69.00 to 80.00, with an average of 75.43.
Past year
1-year forecast
Strong sellStrong buy
Hold
17 ratings
| Buy | 8 | |
| Hold | 9 | |
| Sell | 0 |
12-month price target
| Highest target | 80.00 |
| Average target | 75.43 |
| Lowest target | 69.00 |
| Current price | 68.83 |
Centene valuationWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 23.25
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 13.08
- Price to sales (TTM)What is the P/S ratio? The price-to-sales ratio compares a company's market value with its revenue over the last year: what you pay for each dollar of sales.
- 0.17
- Price to bookWhat is the P/B ratio? The price-to-book ratio compares a company's market value with its book value, the shareholders' equity on its balance sheet.
- 1.53
- EV / EBITDA (TTM)What is EV/EBITDA? EV/EBITDA compares a company's whole value, debt included and cash taken off, with a year of its earnings before interest, tax and depreciation.
- 6.88
Capital structureWhat is enterprise value? Enterprise value is what the whole business costs: the market value of its shares plus its debt minus its cash. It is the price behind EV/EBITDA.
Market capitalization
34.08B USD
+
Total debt
15.54B USD
−
Cash and short-term investments
23.59B USD
=
Enterprise value
26.03B USD
Valuation over time
P/EForward P/EForward P/E · EstimateEstimate
Centene against its own historyWhat does "against its own history" show? The company's latest margins, return on equity, growth, debt and P/E against its own last 5 years: the low, the median and the high, and whether this year is better or worse than usual.
Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.
Its peers: Humana, Cigna, Elevance Health, CVS Health, Molina Healthcare, and Oscar Health, the US Medical - Healthcare Plans companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.
- P/E (today)Above its median23.34.068.3
- Gross marginHighest in 5 years12.2%10.3%12.2%Against its peers: 5 of 7Peers' median 14.1%
- Operating marginLowest in 5 years-3.9%-3.9%1.9%Against its peers: 7 of 7Peers' median 2.2%
- Net marginLowest in 5 years-3.4%-3.4%2.0%Against its peers: 6 of 7Peers' median 1.0%
- Return on equityLowest in 5 years-33.4%-33.4%12.5%Against its peers: 6 of 7Peers' median 9.2%
- Free cash flow marginBelow its median2.2%-0.3%4.7%Against its peers: 3 of 7Peers' median 1.8%
- Revenue growthHighest in 5 years19.4%5.9%19.4%Against its peers: 2 of 7Peers' median 11.5%
- EPS growthLowest in 5 years-315.8%-315.8%139.1%Against its peers: 6 of 7Peers' median -29.2%
- Current ratioBelow its median1.101.061.11Against its peers: 3 of 7Peers' median 0.90
Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.
Centene growth and profitabilityWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- Revenue (TTM)What does TTM (trailing twelve months) mean? TTM (trailing twelve months) is a figure over the latest twelve months of reports: usually the last four quarters added together.
- 203.90B USD
- Net income (TTM)What is an income statement? The income statement shows a company's revenue, costs and profit over a quarter or a year, from sales at the top to net income at the bottom.
- 1.46B USD
- Gross marginWhat are gross, operating and net profit margins? A profit margin is the share of revenue kept as profit: gross margin after the cost of sales, operating margin after running costs, net margin after all costs.
- 20.18%
- Operating margin
- 0.50%
- Net margin
- 0.72%
Revenue / Net income
Revenue Net income Net margin
Centene revenue breakdown
By product
FY2025
75.8%Medicaid21.6%Commercial2.6%Other Operating
| Segment | Revenue | Share of revenue | Change on the year |
|---|---|---|---|
| Medicaid | 147.64B | 75.8% | +18.6% |
| Commercial | 42.00B | 21.6% | +24.6% |
| Other Operating | 5.13B | 2.6% | +4.3% |
Centene financial health
- Cash and short-term investments
- 23.59B USD
- Total debt
- 15.54B USD
- Net cash
- 8.04B USD
- Free cash flow (TTM)What is free cash flow (FCF)? Free cash flow is the cash a company's operations bring in minus what it spends on long-term assets (capex): cash left for debt, dividends and buybacks.
- 3.96B USD
- Current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
- 1.16
- Debt to equityWhat is the debt to equity ratio? Debt to equity is a company's total debt divided by its shareholders' equity: how much it has borrowed for each dollar its owners have in the business.
- 0.70
- Piotroski scoreWhat is the Piotroski F-Score? The Piotroski F-Score rates a company's financial strength from 0 to 9: one point for each of nine tests of profit, debt and efficiency it passes.
- 8 / 9
- Altman Z-scoreWhat is the Altman Z-Score? The Altman Z-Score rolls five financial ratios into one number that signals a company's risk of bankruptcy: over 3 is safe, under 1.8 is distress.
- 3.34
Cash, debt and free cash flow
Cash and short-term investments Total debt Free cash flow
Centene ownershipWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- InstitutionsWhat is institutional ownership? Institutional ownership is the share of a company's stock held by funds, banks and other investment managers, as they report it each quarter on Form 13F.
- 99.77%
- Institutional holders
- 1,067 (+147)
- Free floatWhat is free float? Free float is the part of a company's shares that anyone can buy and sell: all its shares minus those held by insiders, founders and owners of over 5%.
- 98.22%
Who owns the shares
Institutions 99.8% Others 0.2%
As of 30 Jun 2026
Shares free to trade
Free float 486.26M shares ·98.2% Closely held 8.81M shares ·1.8%
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Insider trading
| Quarter | Purchases | Sales | Shares acquired | Shares disposed of |
|---|---|---|---|---|
| Q4 2026 | 0 | 0 | 0.00 | 7.13K |
| Q3 2026 | 0 | 2 | 9.04K | 105.20K |
| Q2 2026 | 0 | 1 | 37.15K | 82.05K |
| Q1 2026 | 0 | 0 | 2.07M | 70.18K |
Shares outstanding
Basic shares Diluted shares Change in diluted shares
Source: Financial Modeling Prep
Title: Centene Corp
Sector: Healthcare
Industry: Medical - Healthcare Plans
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 20 million medical members as of December 2025, mostly in Medicaid (about 64% of membership), the individual exchanges (about 28%), and Medicare (about 5%). The company also provides Medicare Part D pharmaceutical plans.